Entry Name Renal cell carcinoma - Mus musculus (house mouse)
Description Renal cell cancer (RCC) accounts for ~3% of human malignancies and its incidence appears to be rising. Although most cases of RCC seem to occur sporadically, an inherited predisposition to renal cancer accounts for 1-4% of cases. RCC is not a single disease, it has several morphological subtypes. Conventional RCC (clear cell RCC) accounts for ~80% of cases, followed by papillary RCC (10-15%), chromophobe RCC (5%), and collecting duct RCC (<1%). Genes potentially involved in sporadic neoplasms of each particular type are VHL, MET, BHD, and FH respectively. In the absence of VHL, hypoxia-inducible factor alpha (HIF-alpha) accumulates, leading to production of several growth factors, including vascular endothelial growth factor and platelet-derived growth factor. Activated MET mediates a number of biological effects including motility, invasion of extracellular matrix, cellular transformation, prevention of apoptosis and metastasis formation. Loss of functional FH leads to accumulation of fumarate in the cell, triggering inhibition of HPH and preventing targeted pVHL-mediated degradation of HIF-alpha. BHD mutations cause the Birt-Hogg-Dube syndrome and its associated chromophobe, hybrid oncocytic, and conventional (clear cell) RCC.
Class Human Diseases; Cancer: specific typesBRITE hierarchy
Pathway map Ortholog table Organism Mus musculus (house mouse) [GN:
mmu ]
Gene 15251 Hif1a; hypoxia inducible factor 1, alpha subunit [KO:K08268 ]
13819 Epas1; endothelial PAS domain protein 1 [KO:K09095 ]
22346 Vhl; von Hippel-Lindau tumor suppressor [KO:K03871 ]
11863 Arnt; aryl hydrocarbon receptor nuclear translocator [KO:K09097 ]
11864 Arnt2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589 ]
20525 Slc2a1; solute carrier family 2 (facilitated glucose transporter), member 1 [KO:K07299 ]
22339 Vegfa; vascular endothelial growth factor A [KO:K05448 ]
21803 Tgfb1; transforming growth factor, beta 1 [KO:K13375 ]
21808 Tgfb2; transforming growth factor, beta 2 [KO:K13376 ]
21809 Tgfb3; transforming growth factor, beta 3 [KO:K13377 ]
18591 Pdgfb; platelet derived growth factor, B polypeptide [KO:K17386 ]
21802 Tgfa; transforming growth factor alpha [KO:K08774 ]
14388 Gab1; growth factor receptor bound protein 2-associated protein 1 [KO:K09593 ]
18706 Pik3ca; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
18707 Pik3cd; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
74769 Pik3cb; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
18709 Pik3r2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
18708 Pik3r1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
18710 Pik3r3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
12015 Bad; BCL2-associated agonist of cell death [KO:K02158 ]
12928 Crk; v-crk avian sarcoma virus CT10 oncogene homolog [KO:K04438 ]
12929 Crkl; v-crk avian sarcoma virus CT10 oncogene homolog-like [KO:K04438 ]
107746 Rapgef1; Rap guanine nucleotide exchange factor (GEF) 1 [KO:K06277 ]
14784 Grb2; growth factor receptor bound protein 2 [KO:K04364 ]
20662 Sos1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099 ]
20663 Sos2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099 ]
15461 Hras; Harvey rat sarcoma virus oncogene [KO:K02833 ]
16653 Kras; Kirsten rat sarcoma viral oncogene homolog [KO:K07827 ]
23871 Ets1; E26 avian leukemia oncogene 1, 5' domain [KO:K02678 ]
94315 Prcc; papillary renal cell carcinoma (translocation-associated) [KO:K13105 ]
12575 Cdkn1a; cyclin dependent kinase inhibitor 1A [KO:K06625 ]
Compound Reference Authors Cohen HT, McGovern FJ.
Title Renal-cell carcinoma.
Journal Reference Authors Pavlovich CP, Schmidt LS.
Title Searching for the hereditary causes of renal-cell carcinoma.
Journal Reference Authors Linehan WM, Walther MM, Zbar B.
Title The genetic basis of cancer of the kidney.
Journal Reference Authors Kim WY, Kaelin WG.
Title Role of VHL gene mutation in human cancer.
Journal Reference Authors Sudarshan S, Linehan WM, Neckers L.
Title HIF and fumarate hydratase in renal cancer.
Journal Reference Authors Sudarshan S, Pinto PA, Neckers L, Linehan WM.
Title Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer.
Journal Reference Authors Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF.
Title Met, metastasis, motility and more.
Journal Reference Authors Muller-Hocker J, Babaryka G, Schmid I, Jung A
Title Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion.
Journal Reference Authors Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG.
Title Understanding familial and non-familial renal cell cancer.
Journal Reference Authors Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM
Title Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers.
Journal Reference Authors Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G, Cooper CS
Title PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
Journal Reference Authors Medendorp K, van Groningen JJ, Vreede L, Hetterschijt L, Brugmans L, van den Hurk WH, van Kessel AG
Title The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
Journal Related KO pathway LinkDB All DBs
